Overview
Combined pyramidal-extrapyramidal syndrome involves overlapping neurological symptoms characteristic of both pyramidal tract dysfunction (e.g., weakness, spasticity) and extrapyramidal system disorders (e.g., tremors, rigidity, bradykinesia). 1Diagnosis
Clinical Presentation: Presence of both pyramidal signs (weakness, hyperreflexia) and extrapyramidal signs (tremors, dystonia, bradykinesia).
Pharmacovigilance Data: Utilize disproportionality analysis tools like Reporting Odds Ratio (ROR) and confidence intervals to identify signals of disproportionate reporting related to extrapyramidal syndrome. 1
Pharmacological Relevance: Consider pharmacological criteria such as ADR reporting rate without concomitant drugs to enhance signal prioritisation. 1Management
Drug Withdrawal/Adjustment: If drug-induced, consider tapering or discontinuing the offending agent.
Symptomatic Treatment: Use anticholinergics, benzodiazepines, or dopaminergic agents based on predominant symptoms (e.g., antiparkinsonian medications for extrapyramidal symptoms).
Supportive Care: Physical therapy and occupational therapy to manage functional impairments.Special Populations
Pregnancy: Limited data; cautious approach with drug withdrawal if possible, focusing on supportive care. 1
Pediatrics: Specific dosing and safety data scarce; individualized management with close monitoring. 1
Elderly: Increased risk of adverse drug reactions; prioritize non-pharmacological interventions and careful medication review. 1
Comorbidities: Tailor treatment considering interactions and exacerbation risks with existing conditions. 1Key Recommendations
Utilize a pharmacological score (PS-SP) alongside traditional disproportionality methods for prioritizing signals of disproportionate reporting related to extrapyramidal syndrome in pharmacovigilance databases. (Evidence: Expert opinion) 1
In managing drug-induced combined pyramidal-extrapyramidal syndrome, prioritize drug withdrawal or adjustment as initial therapy. (Evidence: Expert opinion) 1
For symptomatic relief, employ targeted pharmacological interventions based on predominant symptoms, complemented by physical and occupational therapy. (Evidence: Expert opinion) 1References
1 Salvo F, Raschi E, Moretti U, Chiarolanza A, Fourrier-Réglat A, Moore N et al.. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. European journal of clinical pharmacology 2014. link